ARTICLE | Company News
Vaxil BioTherapeutics deal
October 18, 2010 7:00 AM UTC
Vaccine company Vaxil reverse-merged with an undisclosed shell company. Vaxil is in Phase I/II testing of ImMucin, a 21mer synthetic vaccine composed of the entire signal peptide domain of the MUC1 ...